Giant-Cell Arteritis Market Outlook 2034: Key Epidemiological Shifts, Emerging Drugs, and Competitive Intelligence by DelveInsight

DelveInsight's latest report, "Giant-Cell Arteritis Market Insight, Epidemiology, and Market Forecast - 2034," offers a comprehensive analysis of Giant-Cell Arteritis (GCA), covering historical and projected epidemiology as well as market trends for approved and emerging therapies across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Gain a deep understanding of the evolving Giant-Cell Arteritis landscape. Download DelveInsight's full report to explore market dynamics, pipeline developments, and upcoming treatment opportunities: Giant-Cell Arteritis Market Size - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights From the Giant-Cell Arteritis Market Report
• Novartis Pharmaceuticals announced on November 5, 2025, a study involving a screening phase of up to four weeks, a two-year treatment duration divided into two phases, followed by a 16-week treatment-free follow-up after the final secukinumab dose.
• In 2023, the United States accounted for 54% of all diagnosed prevalent GCA cases across the 7MM.
• Within the US, classic cranial GCA represented the majority of subtype-specific cases, followed by extracranial/large-vessel GCA.
• Among the EU4 and the UK, the United Kingdom reported the highest number of GCA cases, with Spain showing the lowest.
• In Japan, scalp tenderness was the most common clinical manifestation in 2023, with cases projected to rise through 2034.
• Leading companies shaping the GCA market include AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, among others.
• Promising therapies in development include Mavrilimumab, Prednisone, Baricitinib, and other novel candidates.

Stay ahead with detailed market intelligence and strategic insights. Explore more: Giant-Cell Arteritis Treatment Market Size - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Giant-Cell Arteritis Epidemiology Segmentation (7MM)
• Giant-Cell Arteritis Diagnosed prevalent cases
• Giant-Cell Arteritis Region-specific cases
• Giant-Cell Arteritis Subtype-specific cases
• Giant-Cell Arteritis Gender-specific cases
• Giant-Cell Arteritis Age-specific cases
• Giant-Cell Arteritis Clinical manifestation-specific cases
• Total Giant-Cell Arteritis treated cases

Understand what drives epidemiology trends and future projections: Giant-Cell Arteritis Prevalence - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Approved Therapies in Giant-Cell Arteritis
ACTEMRA/ROACTEMRA (tocilizumab) - Roche
A first-in-class anti-IL-6 receptor therapy targeting IL-6-mediated inflammatory pathways. By blocking IL-6, the treatment reduces inflammation, joint pain, and swelling. ACTEMRA/ROACTEMRA is approved for multiple inflammatory conditions, including GCA, pJIA, sJIA, RA, and CAR-T-induced CRS.

Emerging Therapies in the Pipeline
RINVOQ (upadacitinib) - AbbVie
An oral JAK inhibitor that modulates the JAK-STAT signaling pathway to reduce chronic inflammation. Already approved for several autoimmune diseases in the US, EU, and Japan, RINVOQ is being explored for GCA treatment.

COSENTYX (secukinumab) - Novartis Pharmaceuticals
A fully human anti-IL-17A monoclonal antibody approved for multiple autoimmune conditions, including psoriasis, AS, nr-axSpA, and PsA. It is under investigation for its potential role in GCA.

Explore future treatment innovations: Giant-Cell Arteritis Market Drivers & Barriers - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Giant-Cell Arteritis Market Overview
GCA is named for the distinctive "giant" cells observed in arterial biopsies. While the exact cause remains unclear, research suggests a multifactorial origin involving genetics (HLA associations), immune dysregulation, environmental triggers, infection-related factors, and T-cell activation.

Giant-Cell Arteritis Treatment Landscape
The primary goal of therapy is to prevent severe complications, particularly vision loss. High-dose corticosteroids (40-60 mg daily) are typically prescribed for 3-4 weeks before tapering, although safety concerns persist. In certain cases, DMARDs such as methotrexate, leflunomide, or azathioprine are used to manage the disease or reduce steroid dependency.

Learn more about ongoing clinical research shaping the future of GCA management: Giant-Cell Arteritis Clinical Trials - https://www.delveinsight.com/sample-request/giant-cell-arteritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Giant-Cell Arteritis Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Giant-Cell Arteritis Companies- AbbVie, Novartis Pharmaceuticals, CSL, Kiniksa Pharmaceuticals, Johnson & Johnson, MorphoSys AG, and others.
• Giant-Cell Arteritis Therapies- Mavrilimumab, Prednisone, Baricitinib, and others.
• Giant-Cell Arteritis Therapeutic Assessment: Giant-Cell Arteritis Current Marketed and Giant-Cell Arteritis Emerging Therapies
• Giant-Cell Arteritis Market Dynamics: Giant-Cell Arteritis market drivers and Giant-Cell Arteritis market barriers
• Giant-Cell Arteritis Unmet Needs, KOL's views, Analyst's views, Giant-Cell Arteritis Market Access and Reimbursement

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.